Welcome to Crene Biotechnology!

+86-576-88205808

Catalog No CAS NO Product name
CS0221
572924-54-0
Deforolimus Ridaforolimus
Ridaforolimus, also known as AP23573, is an investigational small-molecule inhibitor of mTOR, a protein that acts as a central reg..
CR2389
1246535-95-4
Desmethyl-VS-5584
Desmethyl-VS-5584 is a demethyl analogue of VS-5584, which is a novel and highly selective PI3K/mTOR kinase inhibitor for the trea..
CR2128
1092788-83-4
PP121
PP121 is a multitargeted dual receptor tyrosine kinases inhibitor. PP121 blocks the proliferation of tumor cells by direct inhibit..
CR2124
1224844-38-5
INK-128 Sapanisertib
Sapanisertib, also known as TAK-228, MLN0128 and INK128, is a TORC1/2 inhibitor, is also an orally bioavailable inhibitor of rapto..
CR2044
1251156-08-7
XL388
XL388 is a Novel Class of Highly Potent, Selective, ATP-Competitive, and Orally Bioavailable Inhibitors of the Mammalian Target of..
CR1480
914913-88-5
Palomid 529
Palomid 529, also known as P529, is a novel PI3K/Akt/mTOR inhibitor. Palomid 529 (P529) inhibits the TORC1 and TORC2 complexes and..
CR1476
1144068-46-1
WYE-125132
WYE-125132, also known as WYE-132, is a highly potent, ATP-competitive, and specific mTOR kinase inhibitor (IC(50): 0.19 +/- 0.07 ..
CR1444
221877-54-9
ABT-578 Zotarolimus
Zotarolimus, also known as ABT-578 and A-179578, is an immunosuppressant. It is a semi-synthetic derivative of rapamycin. It was d..
CR1335
1009298-59-2
AZD2014 Vistusertib
Vistusertib, also known as AZD2014, is an orally bioavailable inhibitor of the mammalian target of rapamycin (mTOR) with potential..
CR1240
936890-98-1
OSI-027
OSI-027 is an orally bioavailable mammalian target of rapamycin (mTOR) kinase inhibitor with potential antineoplastic activity. mT..
首页上一页当前第1/3页共30条记录每页10条123下一页尾页
Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.
Friendly link:

Copyright Copyright (C) 2018-2021Taizhou Crene Biotechnology Co., Ltd.

Address:Economic Developed Zone of Taizhou Zhejiang China.